Anti-varicella-zoster virus antibody
AssigneeZhuhai Trinomab Pharmaceutical Co., Ltd.
InventorsHuaxin Liao, Yueming Wang, Weihong Zheng, Jiaqi Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to neutralizing monoclonal antibodies or antigen-binding fragments thereof that are specific for and bind with high affinity to Varicella-Zoster Virus, and a preparation method for producing such antibodies. The antibodies of the present invention have high efficiency in neutralizing Varicella-Zoster Virus infection. The present invention also relates to the epitope to which the antibodies bind and the use of the antibodies in the diagnosis, prevention and treatment of infected individuals.
Claims19
An isolated anti-VZV monoclonal antibody or antigen-binding fragment thereof, comprising three complementarity determining region CDRs of the heavy chain variable region and three complementarity determining region CDRs of the light chain variable region, wherein
- (i) CDR1 of the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 7, CDR2 of the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 8, CDR3 of the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 9, and CDR1 of the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 10, CDR2 of the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 11, and CDR3 of the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 12;
- (ii) CDR1 of the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 1, CDR2 of the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 2, CDR3 of the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 3, and CDR1 of the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 4, CDR2 of the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 5, and CDR3 of the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 6;
- or
- (iii) CDR1 of the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 13, CDR2 of the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 14, CDR3 of the heavy chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 15, and CDR1 of the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 16, CDR2 of the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 17, and CDR3 of the light chain variable region comprises the amino acid sequence as shown in SEQ ID NO:
- 18.
Dependencies are inferred from the claim text.